p38 Mitogen-activated Protein Kinase Regulation of JB6 Cl41 Cell Transformation Promoted by Epidermal Growth Factor*

Zhiwei He, Yong-Yeon Cho, Guangming Liu, Wei-Ya Ma, Ann M. Bode and Zigang Dong {ddagger}

From the Hormel Institute, University of Minnesota, Austin, Minnesota 55912

Received for publication, April 14, 2003


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The relationship between cell transformation and p38 MAP kinase, a major mitogen-activated protein (MAP) kinase pathway converting signals of various extracellular stimuli into expression of specific target genes through activation of transcription factors, still remains unclear. The aim of the present study was to investigate the role of the p38 MAP kinase pathway in epidermal growth factor (EGF)-induced cell transformation in JB6 cells. Our data show that a dominant negative mutant of p38 MAP (DN-p38) kinase inhibits EGF-promoted JB6 Cl41 cell transformation and that SB202190, an inhibitor of p38 MAP kinase, also inhibits JB6 Cl41 cell transformation in a dose-dependent manner. Moreover, our results show that DN-p38 MAP kinase inhibits the phosphorylation of EGF-stimulated activating transcription factor-2 (ATF-2) and signal transducer and activator of transcription 1 (STAT1). Additionally, DN-p38 MAP kinase inhibits EGF-induced phosphorylation of c-Myc (Thr58/Ser62). Gel shift assays indicate that DN-p38 MAP kinase inhibits EGF-induced activator protein-1 (AP-1) DNA binding in a dose-dependent manner. These results show that p38 MAP kinase plays a key role in the regulation of EGF-induced cell transformation in JB6 cells through regulation of phosphorylation of p38 MAP kinase and activation of its target genes in phosphorylation, c-Myc cell transformation-related genes, and AP-1 binding ability.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The mitogen-activated protein kinases (MAPKs),1 including p38 kinase, c-Jun NH2-terminal kinases (JNKs), extracellular signal-regulated kinases (ERKs), and signal transduction cascades, are vital mediators of many cellular functions such as growth, development, proliferation, differentiation, malignant transformation, inflammation, and apoptosis (13). p38 MAP kinase is activated by cellular stresses including inflammatory cytokines, ultraviolet light, and growth factors, and the activated p38 MAP kinase has been shown to phosphorylate several transcription factors including ATF-2, STAT1, the Max/Myc complex, and myocyte enhancer factor 2 (MEF2) (1, 46). On the other hand, ERKs are predominantly activated by mitogenic stimuli, including mitogens and growth factors, and activated ERKs are involved in cell differentiation and development (2, 3). Although one major function of the p38 kinase and JNKs pathways is regulation of inflammation and apoptosis, in many cases the biological consequences of p38 kinase and JNK activation overlap with those of ERKs in mediation of cell growth and differentiation (2, 3, 6, 7).

Previously, we studied ERKs regulation of epidermal growth factor (EGF)-induced cell transformation in promotion sensitive (P+) derivatives of the mouse epidermal JB6 cell line (8). Results showed that inhibition of ERKs appeared to be an important contributor to the tumor promotion-resistant phenotype in JB6 cells. A recent study showed that the p38 kinase and JNKs pathways cooperate to transactivate the vitamin D receptor through the c-Jun/activator protein-1 (AP-1) (9). This result indicates that a connection exists between p38 MAP kinase and AP-1. But AP-1 activation is involved in JB6 cell transformation promoted by EGF and the phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate (TPA) (10, 11). AP-1 is a dimeric complex consisting of proteins encoded by the jun and fos gene families, and the AP-1 binding region in these genes is referred to as the TPA response element (TRE). AP-1 induces the transcription of genes that are related to cell proliferation, metastasis, and metabolism (1214). Increased AP-1 activity is associated with malignant transformation, and repression of AP-1 activity has been shown to lead to suppression of cell transformation and tumor promotion (15).

Activation of MAP kinase cascades is known to play a considerable role in malignant transformation (3, 8). However, whether p38 MAP kinase is involved in the regulation of cell transformation is not known. A recent study showed that only p38 MAP kinase, a MAP kinase usually associated with stress responses, growth arrest, and apoptosis, was consistently increased in human non-small cell lung cancer samples compared with the normal tissues examined (16). More interesting are the results showing that ERKs and JNKs, the MAP kinase pathways traditionally associated with cell growth and perhaps malignant transformation, were not activated in the human non-small cell lung tumor samples. These results indicate that p38 MAP kinase is probably involved in malignant cell transformation. The purpose of this research project was to explore the mechanism of p38-mediated JB6 cell transformation using CMV-neo plasmid-transfected JB6 cells and dominant negative mutant p38 (DN-p38) plasmid-transfected JB6 cells following EGF stimulation. The results obtained show that p38 MAP kinase plays a critical role in regulation of JB6 Cl41 cell transformation promoted by EGF through the inhibition of the phosphorylation of ATF-2, STAT1, and c-Myc and the repression of AP-1 binding ability.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Materials—Eagle's minimal essential medium (MEM), L-glutamine, and LipofectAMINETM 2000 reagent were from Invitrogen; EGF and SB202190 were from Calbiochem-Novabiochem. Fetal bovine serum (FBS) was from Gemini Bio-Product (Calabasas, CA). Penicillin, streptomycin, and gentamicin sulfate were from BioWhittaker, Inc. (Walkersville, MD). Folin & Ciocalteu's phenol reagent was from Pierce, and polyvinylidene difluoride (PVDF) membrane was from Millipore (Bedford, MA). Antibodies to detect the phosphorylation of p38 kinase, ERKs, JNKs, ATF-2, STAT1, and c-Myc and the non-phosphorylated levels of p38 kinase, ERKs, JNKs, ATF-2, STAT1 and the c-Myc protein were from Upstate Biotechnology (Lake Placid, NY). [{alpha}-32P]ATP was from Amersham Biosciences.

Cell Culture and Establishment of Stably Transfected JB6 Cells— Using the CMV-neo plasmid and DN-p38 kinase plasmid, we established stable transfectants according to the protocol from Invitrogen. All of these cells were selected in media containing 400 µg/ml of G-418 for 2 weeks, and then the G418 concentration was decreased to 200 µg/ml and maintained. Empty vector CMV-neo plasmid-transfected JB6 cells (Cl41 CMV-neo) and DN-p38 plasmid-transfected JB6 cells (Cl41 DN-p38) were cultured as adherent monolayers in MEM supplemented with 5% (v/v) heat-inactivated FBS and glutamine (2 mM) at 37 °C in a humidified atmosphere of 5% CO2.

Immunoblotting—Cl41 CMV-neo and Cl41 DN-p38 cells were cultured as described above, and immunoblotting was carried out as described previously (17). In brief, cells were cultured to 80% confluence and then starved in 0.1% FBS/MEM for 24 h at 37 °C in a 5% CO2 incubator. The media were changed to fresh 0.1% FBS/MEM, the cells were incubated for another 2–4 h at 37 °C, and the cells were then treated with EGF for different time periods at the concentrations indicated. Cells were then disrupted with lysis buffer (62.5 mM Tris-HCl, pH 6.8, 50 mM dithiothreitol, 2% (w/v) SDS, 10% (v/v) glycerol, and 0.1% bromphenol blue). The lysed samples were transferred into fresh 1.5-ml tubes and sonicated for 5–10 s. Samples containing an equal amount of protein were loaded into each lane of an SDS-polyacrylamide gel for electrophoresis and subsequently transferred onto a polyvinylidene difluoride membrane. Phosphorylation of ERKs, JNKs, ATF-2, STAT1, and c-Myc were selectively detected by Western immunoblotting using a chemiluminescent detection system and a phospho-specific antibody against phosphorylation of p38 kinase (Thr180/Tyr182), ERKs (Thr202/Tyr204), JNKs (Thr183/Tyr185), ATF-2 (Thr71), STAT1 (Ser727), and c-Myc (Thr58/Ser62). Antibodies against non-phosphorylated levels of p38 kinase, ERKs, JNKs, ATF-2, STAT1, and c-Myc were used as internal controls to determine loading efficiency.

p38 MAP Kinase Activity Assay—A p38 MAP kinase activity assay was carried out following the instructions from Cell Signaling Technology Inc. Cl41 CMV-neo cells and Cl41 DN-p38 cells were starved in 0.1% FBS/MEM at 37 °C in a 5% CO2 incubator for 24 h and then treated with EGF (10 ng/ml) for various times as indicated. Cells were harvested with lysis buffer (20 mM Tris, pH 7.5, 5 mM {beta}-glycerolphosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, and 10 mM MgCl2), and protein concentration was determined by the Modified-Lowry protein assay. Total cell lysates were centrifuged at 10,000 rpm for 10 min at 4 °C. The cell extracts were incubated overnight at 4 °C with 20 µlofan immobilized dual phospho-specific p38 MAPK (Thr180/Tyr182) monoclonal antibody. After extensive washing, the kinase reaction was performed at 37 °C for 10 min in the presence of 100 µM ATP and 2 µg of an ATF-2 fusion protein. Phosphorylation of ATF-2 at Thr71 was measured by Western blot using a specific antibody against phosphorylation of ATF-2 (Thr71).

AP-1 DNA Binding Study—Nuclear protein extracts were prepared from cells by a modification of the method of Ye et al. (18). Briefly, Cl41 CMV-neo cells and Cl41 DN-p38 cells were cultured in 10-cm dishes and starved in 0.1% FBS/MEM at 37 °C in a 5% CO2 incubator. After 24 h of starvation, the cells were exposed to different concentrations of EGF for another 12 h. The cells were then harvested and disrupted in 500 µl of lysis buffer A (50 mM KCl, 0.5% Nonidet P-40, 100 µM dithiothreitol, 25 mM HEPES, pH 7.8, 10 µg/ml leupeptin, 25 µg/ml aprotinin, and 1 mM phenylmethylsulfonyl fluoride). After a 1-min centrifugation (16,000 x g at 4 °C), the pellets containing the nuclei were washed once with 500 µl of Buffer B (Buffer A without Nonidet P-40). The pellets were then resuspended in 100 µl of extraction buffer (Buffer B, but with 500 mM KCl and 10% glycerol) and strongly shaken at 4 °C for 30 min. After a 10-min centrifugation (16,000 x g at 4 °C), the supernatant solutions were moved into fresh tubes and stored at –70 °C until analysis. The DNA binding reaction was incubated at room temperature for 30 min in a mixture containing 5 µg of nuclear protein, 1 µg of poly(dI·dC), and 15,000 cpm of a {alpha}-32P-labeled double-stranded AP-1 oligonucleotide (5'-CGCTTGATGAGTCAGCCGGAA-3'). The samples were separated on a 5% polyacrylamide gel, and the gels were analyzed using the Storm 840 phosphorimaging system (Amersham Biosciences).

Anchorage-independent Transformation Assay—The role of p38 MAP kinase in EGF-promoted cell transformation was investigated in Cl41 CMV-neo cells and Cl41 DN-p38 cells. The effect of the inhibitor SB202190 on EGF-promoted cell transformation was explored in JB6 Cl41 cells. In brief, 8 x 103/ml cells were exposed to EGF (5–10 ng/ml) with or without SB202190 (0.1–0.5 µM) in 1 ml of 0.3% basal medium Eagle (BME) agar containing 10% FBS. The cultures were maintained at 37 °C in a 5% CO2 incubator for 10 days, and the cell colonies were scored as described by Colburn et al. (19). The effect of DN-p38 on JB6 Cl41 cell transformation is presented as colony number per 10,000 seeded Cl41 CMV-neo cells or Cl41 DN-p38 cells in soft agar, and the effect of SB202190 on JB6 cell transformation is also presented as the number of colonies per 10,000 cells.

Amplification, Mutagenesis, and Expression Vector Construction of the STAT1—To further explore the role of transcriptional factor STAT1, one of the targets of p38 MAP kinase in JB6 Cl41 cell transformation, we gained stable expression of the point mutation at S727A (STAT1-S727A) and expression of only plasmid pcDNA 3.1. The JB6 Cl41 cell lines used included JB6 Cl41-STAT1-mt (S727A) and JB6 Cl41-pcDNA3.1 cells. All of these cells were employed to detect cell transformation ability promoted by EGF. In brief, the cDNA fragment of STAT1, including a 2253-base pair open reading frame (ORF), was reverse-transcribed with an oligo(dT) primer and SuperScript II RNase H reverse transcriptase (Invitrogen), amplified by PCR with primers 5'-GCA GGA TCC TGT CTC AGT GGT ACG AAC T-3' (BamHI site underlined) and 5'-TCG ACG CGT TGC TCT ATA CTG TGT TCA TC-3' (MluI site underlined), and then cloned into the pACT vector (Promega, Madison, WI) via the BamHI and MluI restriction sites. The STAT1 coding fragment digested with BamHI/EcoRV from the pACT was cloned into the BamHI/SmaI sites of the pUC19 vector. To introduce the point mutation in the position of the Ser727 residue, a pair of sense and antisense primers for STAT1 S727A, 5'-C CTG CTC CCC ATG GCT CCT GAG GAG-3' and 5'-CTC CTC AGG AGC CAT GGG GAG CAG G-3' (underlined nucleotides indicate the codon coding a mutated amino acid) were synthesized (Sigma). Then, the nucleotide substitutions were accomplished using the QuikChange site-directed mutagenesis kit (Stratagene). To construct the mammalian expression vector, the PCR products of wild type STAT1 and STAT1-S727A were amplified using primers 5'-CGG GAT CCA TGT CTC AGT GGT ACG AAC TTC A-3' (BamHI site underlined) and 5'-GGG ATA TCC TAT ACT GTG TTC ATC ATA CTG-3' (EcoRV site underlined) and then introduced into same restriction sites of pcDNA3.1-neo (Invitrogen). All of products, including cloning, mutagenesis, or expression vectors, were confirmed by DNA sequence analysis (Sigma).

Statistical Analysis—Significant differences between groups were determined by the Student's and Welch's t tests.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
EGF Induces Phosphorylation of p38 Kinase and ERKs but Not JNKs—MAPKs play very important roles in the transformation of mouse JB6 Cl41 cells stimulated by EGF or TPA (8). Our results showed that EGF induced phosphorylation of ERKs in both time- and dose-dependent manners (Fig. 1, A and G). We further investigated whether EGF also contributed to phosphorylation of other members of MAPKs such as p38 kinase and JNKs. Our results showed that EGF also induced phosphorylation of p38 kinase in both time- and dose-dependent manners (Fig. 1, C and I), but not JNKs (Fig. 1, E and K). These data correspond with other findings that show that EGF mediates cell growth through both MEK/ERK and p38 kinase signal transduction pathways (20, 21).



View larger version (36K):
[in this window]
[in a new window]
 
FIG. 1.
EGF induces phosphorylation of p38 kinase and ERKs but not JNKs. JB6 Cl41 cells were cultured in 5% FBS/MEM and starved in 0.1% FBS/MEM at 37 °C in a 5% CO2 atmosphere for 24 h. Cells were then incubated in fresh 0.1% FBS/MEM for another 2 h before being treated with EGF (10 ng/ml) for 5–60 min or EGF (5–20 ng/ml) for 30 min. Phosphorylation of p38 kinase (C and I), ERKs (A and G), and JNKs (E and K) were determined by Western blot analysis as described under "Experimental Procedures" using specific antibodies against phosphorylation of p38 kinase (Thr180/Tyr182), ERKs and JNKs. Total protein levels of p38 kinase (D and J), ERKs (B and H), and JNKs (F and L) were determined as described under "Experimental Procedures" using corresponding antibodies against non-phosphorylated proteins.

 

The p38 Kinase Inhibitor SB202190 Inhibits the EGF-induced Phosphorylation of p38 Kinase but Not ERKs—To explore the role of p38 kinase in the EGF-stimulated signal transduction pathway, SB202190, a p38 kinase inhibitor (2225), was used to pre-treat JB6 cells at different doses for 1 h. Our results showed that SB202190 inhibited the EGF-induced phosphorylation of p38 kinase in a dose-dependent manner (Fig. 2B) but had no effect on EGF-induced ERK phosphorylation (Fig. 2A). These results indicate that SB202190 can specifically inhibit EGF-induced p38 kinase phosphorylation.



View larger version (24K):
[in this window]
[in a new window]
 
FIG. 2.
SB202190 inhibits phosphorylation of p38 kinase but not ERKs. JB6 cells were cultured and starved as described above. SB202190 (0.25–1.0 µM) was used to pretreat JB6 cells for 1 h, and then JB6 cells were treated with EGF (10 ng/ml) for 30 min. Phosphorylation of ERKs (A) and p38 kinase (B) were determined by Western blot analysis as described under "Experimental Procedures" using specific antibodies against phosphorylation of p38 kinase and ERKs. Total protein levels of p38 kinase and ERKs were determined as described above.

 

The p38 Kinase Inhibitor SB202190 Suppresses JB6 Cl41 Cell Anchorage-independent Transformation Promoted by EGF—To confirm the role of p38 MAP kinase in JB6 cell transformation, we explored EGF-promoted cell transformation in JB6 Cl41 cells using the p38 kinase inhibitor SB202190. JB6 cells were treated with EGF (10 ng/ml) alone or with SB202190 (0.1–0.5 µM) in a soft agar matrix at 37 °C in a 5% CO2 incubator for 10 days. The colony number was determined as described previously, and experiments were repeated three times. Compared with JB6 Cl41 cells stimulated only by EGF, the colony numbers were greatly decreased after EGF and SB202190 treatment, and this inhibition occurred in a dose-dependent manner (Fig. 3, AE). These data provide more evidence that p38 MAP kinase contributes to JB6 cell transformation promoted by EGF, and this study is the first to report that SB202190 inhibits EGF-induced JB6 Cl41 cell transformation.



View larger version (53K):
[in this window]
[in a new window]
 
FIG. 3.
SB202190 inhibits JB6 Cl41 anchorage-independent transformation promoted by EGF. JB6 Cl41 anchorage-independent transformation promoted by EGF was performed as described previously. Final concentrations of 0.1 or 0.5 µM SB202190 were added into soft agar, and the colonies were counted automatically after 10 days of incubation at 37 °C in a 5% CO2 atmosphere. Almost no colony formation was observed in JB6 cells without EGF stimulation (A), and many colonies were observed in JB6 Cl41 cells treated only with EGF (B). SB202190 suppressed EGF-stimulated JB6 Cl41 cell colony formation in a dose-dependent manner (C and D). The average number of colonies was determined from three separate experiments; ctrl, control (E).

 

DN-p38 MAP Kinase Inhibits Phosphorylation of p38 Kinase but Not ERKs or JNKs—Because SB202190 may affect other molecular targets besides p38 kinase, we used stable transfectants of Cl41 CMV-neo cells and Cl41 DN-p38 cells to further study the biological activity of p38 kinase (24, 25). Cells were treated with EGF at various concentrations for different times, and Western blot analysis was used to determine the level of phosphorylation of p38 kinase, ERKs, and JNKs using specific antibodies. Our data showed that EGF induced phosphorylation of p38 kinase and ERKs in a dose- (Fig. 4, A and C) and time-dependent (Fig. 4, G and I) manner but had no effect on phosphorylation of JNKs (Fig. 4, E and K). Total protein levels of these kinases did not change (Fig. 4, B, D, F, H, J, and L). These data also showed that DN-p38 inhibited the EGF-induced phosphorylation of p38 kinase in a time- and dose-dependent manner but had no effect on phosphorylation of ERKs or JNKs. Results indicate that ERKs and p38 kinase, but not JNKs, are involved in EGF-stimulated cell signal transduction.



View larger version (36K):
[in this window]
[in a new window]
 
FIG. 4.
DN-p38 MAP kinase inhibits phosphorylation of p38 kinase but not ERKs or JNKs. Empty vector CMV-neo plasmidtransfected JB6 Cl41 cells (Cl41 CMV-neo) and dominant negative p38 plasmid-transfected JB6 Cl41 cells (Cl41 DN-p38) were starved in 0.1% FBS/MEM at 37 °C in a 5% CO2 atmosphere for 24 h. Cells were then incubated in fresh 0.1% FBS/MEM for another 2 h before being treated with EGF (10 ng/ml) for 15–60 min or EGF (5–20 ng/ml) for 30 min. Phosphorylation of p38 kinase (A and G), ERKs (C and I), and JNKs (E and K) was determined by Western blot analysis as described under "Experimental Procedures" using specific antibodies against phosphorylation of p38 kinase (Thr180/Tyr182), ERKs, and JNKs. Total protein levels of p38 kinase (B and H), ERKs (D and J), and JNKs (F and L) were determined as described under "Experimental Procedures" using corresponding antibodies against non-phosphorylated proteins.

 

DN-p38 Inhibits Anchorage-independent Transformation Promoted by EGF—From the results described above, we hypothesized that p38 kinase could have a role in regulating JB6 cell transformation. Cell transformation was assessed using our previously developed methods (26, 27). Cl41 CMV-neo cells and Cl41 DN-p38 cells were treated separately with EGF (5–10 ng/ml) in a soft agar matrix at 37 °C in a 5% CO2 incubator for 10 days. The number of colonies formed was counted automatically by computer, and the same experiment was repeated three times. Our results showed that DN-p38 strongly inhibited the formation of EGF-induced colonies (Fig. 5D) compared with control cells (Fig. 5B). The inhibition was evident not only in colony number (Fig. 5E) but also in colony size (Fig. 5, B versus D). However, untreated Cl41 CMV-neo cells and Cl41 DN-p38 cells showed no colony formation (Fig. 5, A and C). These data indicate that p38 MAP kinase is involved in JB6 cell transformation as a positive regulator rather than an inhibitor.



View larger version (50K):
[in this window]
[in a new window]
 
FIG. 5.
DN-p38 MAP kinase inhibits EGF-induced JB6 Cl41 anchorage-independent transformation. Cl41 CMV-neo cells and Cl41 DN-p38 cells were used to study cell transformation as described under "Experimental Procedures." Cells (8 x 103/ml) were incubated in soft agar at 37 °C in a 5% CO2 atmosphere for 10 days. Colonies of Cl41 CMV-neo cells (A and B) and Cl41 DN-p38 cells (C and D) were counted automatically as described previously. The average colony number was calculated from three separate experiments; ctrl, control (E).

 

DN-p38 Inhibits EGF-induced p38 MAP Kinase Activity—To further confirm that the Cl41 DN-p38 stable transfectant cells work as expected, p38 MAPK activity toward its substrate, ATF-2, was assayed. Cells were treated with EGF (10 ng/ml) for the indicated times, and the cell extracts were incubated with an immobilized p38 kinase antibody. An ATF-2 fusion protein was used as a substrate of p38 MAP kinase, and phosphorylation of ATF-2 at Thr71 was detected by Western blot. Our results showed that EGF-induced phosphorylation of ATF-2 at Thr71 was decreased distinctly in Cl41 DN-p38 cells compared with Cl41 CMV-neo cells (Fig. 6). These data indicate that p38 kinase has a role in EGF-induced phosphorylation of ATF-2.



View larger version (13K):
[in this window]
[in a new window]
 
FIG. 6.
DN-p38 MAP kinase inhibits p38 MAP kinase activity in vivo. Cl41 CMV-neo cells and Cl41 DN-p38 cells were seeded in 100-mm dishes with 5% FBS/MEM and incubated at 37 °C in a 5% CO2 atmosphere for 24 h. Cells were starved as described previously. Cells were then incubated in fresh 0.1% FBS/MEM for another 2 h before being treated with EGF (10 ng/ml) for the indicated time periods. Cells were added to lysis buffer as described under "Experimental Procedures," and the same amount of extracted proteins was immunoprecipitated with a monoclonal phospho-specific antibody against p38 MAP kinase (Thr180/Tyr182). The resulting immunoprecipitate was incubated with an ATF-2 fusion protein in the presence of ATP and kinase buffer. Phosphorylation of ATF-2 at Thr71 was measured by Western blotting using the phospho-ATF-2 (Thr71) antibody (A), and total ATF-2 protein level was determined by Western blot using an antibody against nonphosphorylated ATF-2 protein (B).

 

DN-p38 Inhibits EGF-induced Phosphorylation of STAT1 at Ser727 in a Time- and Dose-dependent Manner—STAT1 is downstream of p38 MAP kinase and is a transcription factor that mediates cytokine and growth factor-induced signals that culminate in various biological responses, including proliferation and differentiation (28). Cl41 DN-p38 cells and Cl41 CMV-neo cells were treated separately for various times and at various doses with EGF. We found that EGF (10 ng/ml) strongly induced phosphorylation of STAT1 at Ser727 in Cl41 CMV-neo cells, but the phosphorylation of STAT1 at Ser727 in Cl41 DN-p38 cells was relatively weak. However, phosphorylation of STAT1 gradually decreased within 120 min in both cell lines (Fig. 7A). Non-phosphorylated levels of STAT1 were unchanged throughout the time course and dose course (Fig. 7, B and D). EGF-induced phosphorylation of STAT1 at Ser727 gradually increased with increasing EGF concentrations (Fig. 7C) with no change in non-phosphorylated levels of STAT1 (Fig. 7D).



View larger version (29K):
[in this window]
[in a new window]
 
FIG. 7.
DN-p38 MAP kinase inhibits phosphorylation of STAT1 (Ser727). Culture and starvation of Cl CMV-neo cells and Cl41 DN-p38 cells were performed as described above. In the time course study (A and B), cells were treated with EGF (10 ng/ml) for the indicated time periods and then harvested with lysis buffer, and the protein concentration of each sample was determined. Equal amounts of protein were separated by 8% SDS-PAGE gel and analyzed by Western blotting. Phosphorylation of STAT1 at Ser727 was detected using a specific phospho-STAT1 (Ser727) antibody (A). Total STAT1 protein levels were detected by a non-phospho-STAT1 antibody (B). In the dose course study (C and D), Cl41 CMV-neo cells, and Cl41 DN-p38 cells were treated with EGF at the indicated concentration for 15 min. Phosphorylation of STAT1 at Ser727 (C) and total STAT1 protein levels (D) were detected as described above.

 

DN-p38 Inhibits Phosphorylation of c-Myc at Thr58/Ser62To understand the mechanism of p38 MAP kinase in the regulation of JB6 cell transformation, we investigated the phosphorylation of c-Myc by Western blot using a specific antibody against phosphorylation of c-Myc at Thr58/Ser62. The c-Myc oncoprotein is associated with cell growth, development, and malignant transformation in human tumors and cell lines (29, 30). The active c-Myc also contributes to cell transforming potencies in rat embryo cells (31). In this study, our results showed that phosphorylation of c-Myc at Thr58/Ser62 was increased after CMV-neo JB6 cells were treated from 1–4 h with EGF (10 ng/ml), but phosphorylation of c-Myc at Thr58/Ser62 in DN-p38-JB6 cells was relatively less within the same time course (Fig. 8A). EGF had no effect on total c-Myc protein levels in Cl41 CMV-neo cells or Cl41 DN-p38 cells (Fig. 8, B and D). Moreover, we studied the effects of various doses of EGF on phosphorylation of c-Myc at Thr58/Ser62. Results showed that phosphorylation of c-Myc at Thr58/Ser62 increased in Cl41 CMV-neo cells but was only slightly changed in Cl41 DN-p38 cells after cells were treated with EGF (5–20 ng/ml) (Fig. 8C). These data indicate that phosphorylation of c-Myc at Thr58/Ser62 is induced by EGF in a time- and dose-dependent manner in Cl41 CMV-neo cells and that DN-p38 inhibits the phosphorylation of c-Myc at Thr58/Ser62.



View larger version (21K):
[in this window]
[in a new window]
 
FIG. 8.
DN-p38 MAP kinase inhibits phosphorylation of c-Myc at Thr58/Ser62. Culture and starvation of Cl41 CMV-neo cells and Cl41 DN-p38 cells were performed as described above. In the time course study (A and B), cells were treated with EGF (10 ng/ml) for the indicated time periods and then harvested with lysis buffer, and the protein concentration of each sample protein was determined. Western blotting was employed to analyze the phosphorylation of c-Myc at serine 63 using a specific phospho-c-Myc (Thr58/Ser62) antibody (A). Total c-Myc protein levels were detected by a non-phospho-c-Myc antibody (B). In the dose course study (C and D), Neo-JB6 Cl41 and DN-p38-JB6 Cl41 cells were treated with EGF at the indicated concentration for 4 h. Phosphorylation of c-Myc at Thr58/Ser62 (C) and total c-Myc protein levels (D) were detected as described above.

 

A Mutant of STAT1 (S727A) Suppresses JB6 Cl41 Cell Anchorage-independent Transformation Promoted by EGF—Stable transfectant JB6 Cl41-STAT1 (S727A) cells expressing of STAT1 (S727A) and JB6 Cl41-pcDNA3.1 cells expressing plasmid pcDNA3.1 cells were employed to detect the cell transformation ability promoted by EGF. Cells were treated with EGF (10 ng/ml) in a soft agar matrix at 37 °C in a 5% CO2 incubator for 10 days. The colony number was determined as described previously (8). The colony numbers were greatly decreased in JB6 Cl41-STAT1 (S727A) cells promoted by EGF, but there were many more colonies in JB6 Cl41 cells and JB6 Cl41-pcDNA 3.1 stimulated by EGF under the same condition (Fig. 9, A–F). These data indicate that STAT1, one of the targets of p38 MAP kinase, also contributes to JB6 Cl41 cell transformation promoted by EGF.



View larger version (35K):
[in this window]
[in a new window]
 
FIG. 9.
Mutant of STAT1 (S727A) suppresses JB6 Cl41 cell anchorage-independent transformation promoted by EGF. Cellular anchorage-independent transformation promoted by EGF was performed as described previously. Final concentrations of EGF (10 ng/ml) were added into soft agar, and the colonies were counted automatically after 10 days of incubation at 37 °C in a 5% CO2 atmosphere. Almost no colony formation was observed in JB6 cells and JB6 Cl41-pcDNA3.1 cells without EGF stimulation (A and B), and many colonies were observed in JB6 Cl41 and JB6 Cl41-pcDNA3.1 cells treated only with EGF (C, D, and E). But very few colonies were counted in JB6 Cl41-pcDNA 3.1-STAT1 (S727A) cells (E). The average number of colonies was determined from three separate experiments; ctrl, control (F).

 

DN-p38 Inhibits EGF-induced AP-1 Binding Activity—AP-1 induces gene transcription by binding to the TPA response element site in the promoter region of its target gene and is required for cell proliferation, differentiation, and malignant transformation (32, 33). Double-stranded AP-1 oligonucleotides were labeled with {gamma}-32P, and electrophoretic mobility-shift assays were used to measured AP-1 DNA binding activity. Our results showed that AP-1 binding was decreased in Cl41 DN-p38 cells (Fig. 10, A and B, lanes 3, 4, and 5) compared with that in Cl41 CMV-neo cells (Fig. 10, A and B, lanes 7, 8, and 9) after cells were treated with EGF (5–20 ng/ml) for 12 h. However no significant change was observed between DN-p38-JB6 cells and Neo-JB6 cells without EGF stimulation (Fig. 10, A and B, lanes 2 and 6). To confirm that the electrophoretic mobility-shift band was specific for AP-1 binding, a 10-fold amount of unlabeled AP-1 oligonucleotide was added, and results showed that the AP-1 binding band was completely removed (Fig. 10, A and B, lane 1). These data indicate that DN-p38 inhibits EGF-induced AP-1 binding ability.



View larger version (22K):
[in this window]
[in a new window]
 
FIG. 10.
DN-p38 MAP kinase inhibits EGF-induced AP-1 DNA binding. Cl41 CMV-neo cells and Cl41 DN-p38 cells were treated with EGF, and nuclear proteins were extracted as described under "Experimental Procedures." A, Cl41 DN-p38 cells effectively blocked EGF-induced AP-1 DNA binding (lanes 3–5) compared with EGF-induced AP-1 DNA binding in Cl41 CMV-neo cells (lanes 7–9). B, quantitation analysis of panel A from three separate electrophoretic mobility shift assays performed using nuclear extracts from different cell preparations.

 


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Previous studies show that ERKs are involved in the JB6 cell transformation promoted by EGF or TPA (8), but an understanding of the role of p38 MAP kinase in cell transformation still remains unclear. In this study, we found that p38 MAP kinase plays a critical role in JB6 Cl41 cell transformation promoted by EGF. Both DN-p38 and the p38 MAP kinase inhibitor SB202190 suppressed JB6 Cl41 cell transformation promoted by EGF. DN-p38 inhibited EGF-stimulated phosphorylation of ATF-2, STAT1, and c-Myc, and gel shift assay results showed that DN-p38 inhibits AP-1 binding ability. These results indicate that p38 MAP kinase is involved in regulation of JB6 Cl41 cell transformation promoted by EGF through the inhibition of phosphorylation of its downstream factors, including ATF-2, STAT1, c-Myc, and also AP-1 DNA binding.

Many studies indicate that EGF induces the phosphorylation of ERKs and p38 MAP kinase (21, 3436). The ERK pathway is associated with activation of the EGF receptor and has been shown to play a major role in promoting several tumor phenotypes. However, the JNKs pathway has not been shown to be activated through the EGF receptor but is instead more uniformly stimulated by cellular stresses and cytokines (21). Our present data also show that EGF only induces the phosphorylation of ERKs and p38 MAP kinase but not JNKs (Fig. 1). SB202190 and DN-p38 only inhibit EGF-induced phosphorylation of p38 MAP kinase but not ERKs (Figs. 2 and 4). These results indicate that ERKs and p38 MAP kinase, but not JNKs, independently participate in EGF-stimulated cell signal transduction.

The p38 MAP kinase is usually associated with stress responses, growth arrest, and apoptosis (1, 2, 4). But a recent study (16) showed that it was activated in human lung cancer samples, suggesting an additional role for this pathway in malignant cell growth or transformation. The present study is the first to report that p38 MAP kinase is involved in JB6 Cl41 cell transformation promoted by EGF. SB202190, a p38 MAP kinase inhibitor, distinctly inhibited colony formation in EGF-promoted JB6 Cl41 cell transformation (Fig. 3). To eliminate the effects of SB202190 on other molecular targets, we successfully constructed a stable transfectant of JB6 Cl41 cells expressing a dominant negative mutant of p38 kinase and DN-p38 according to the method described previously (37, 38). Our results showed that the number of colonies in EGF-treated Cl41 DN-p38 cells was significantly decreased compared with the number of colonies in Cl41 CMV-neo cells (Fig. 5). These data indicate that p38 MAP kinase plays a critical role in JB6 Cl41 cell transformation promoted by EGF.

To explore the mechanism of p38 kinase in the regulation of JB6 cell transformation, we first determined whether p38 MAP kinase activity was inhibited in Cl41 DN-p38 cells. Our results show that DN-p38 distinctly inhibits EGF-induced phosphorylation of ATF-2 at Thr71 (Fig. 6). Thr71 is a major ATF-2 phosphorylation site required for transcriptional activity, and a high level of phosphorylated ATF-2 protein correlates with malignant phenotypes in the multistage mouse skin carcinogenesis model (39). One recent study showed that EGF activates transcription factor ATF-2 through a two-step mechanism. The Raf-MEK-ERK pathway induces phosphorylation of ATF-2 (Thr71), whereas subsequent ATF-2 Thr69 phosphorylation requires the Ral-RalGDS-Src-p38 MAP kinase pathway (40). Moreover, cooperation between ERKs and p38 kinase was found to be essential for ATF-2 activation by EGF (41).

Some of the STAT family members have a role in the regulation of cellular transformation (42). A recent study showed that STAT3 activation is required for interleukin-6-induced transformation in tumor promotion-sensitive mouse skin epithelial cells (43). Another report showed that transformation of normal fibroblasts cells with E1A + Ha-Ras oncogenes causes a constitutive activation of STAT1 and STAT3 transcription factors (44). In this study, we found that EGF-induced phosphorylation of STAT1 (Ser727) also decreased in Cl41 DN-p38 cells but increased in Cl41 CMV-neo cells after the cells were separately treated with EGF (10 ng/ml) (Fig. 7). We successfully employed directed point mutation technology to obtain a mutant of STAT1 at Ser727 (Ser -> Ala). Stable transfectant of JB6 Cl41-STAT1 (S727A) cells expressing mutant of STAT1 at Ser727 (Ser727 (Ser -> Ala) displayed its ability to inhibit cell transformation in JB6 Cl41 cells promoted by EGF (Fig. 9). These results indicate that EGF-induced phosphorylation of STAT1 at Ser727 is at least partially dependent on p38 MAP kinase and that STAT1 is involved in JB6 cell transformation promoted by EGF.

Studies show that the c-Myc oncoprotein is associated with cancer cell proliferation and transformation (45, 46). In this study, we also found that DN-p38 inhibited EGF-induced phosphorylation of c-Myc, indicating that p38 MAP kinase mediates EGF-induced c-Myc phosphorylation (Fig. 8). Thus, p38 MAP kinase may be involved in cell transformation through phosphorylation of c-Myc. On the other hand, AP-1, a heterodimer commonly comprised of the basic leucine zipper proteins Fos and Jun, plays a very important role in the induction of neoplastic transformation and the multiple genes involved in cell proliferation, differentiation, and inflammation (47, 48). Blocking the tumor promoter-induced activation of AP-1 was shown to inhibit neoplastic transformation in JB6 mouse epidermal cells (49). One recent study (47) showed that p38 MAPK and ERK inhibition with SB203580 and PD98059, respectively, significantly inhibited silica-induced AP-1 activation. These findings demonstrate that AP-1 activation may be mediated through the p38 MAPK and ERKs pathways (47). In the present research, EGF-induced AP-1 binding ability decreased in Cl41 DN-p38 cells compared with Cl41 CMV-neo cells (Fig. 10). These data provide further evidence that EGF-induced AP-1 binding ability is mediated through p38 MAP kinase and that DN-p38 MAP kinase represses EGF-induced JB6 Cl41 cell transformation through inhibition of AP-1 DNA binding ability.

In summary, we report for the first time that p38 MAP kinase mediates EGF-promoted JB6 Cl41 cell transformation through regulation of the phosphorylation of its downstream factors, such as STAT1, ATF-2, and c-Myc, and also AP-1 DNA binding ability (Fig. 11). This study illustrates that p38 MAP kinase is another new pathway involved in JB6 Cl41 cell transformation promoted by EGF.



View larger version (14K):
[in this window]
[in a new window]
 
FIG. 11.
Proposed signal transduction pathways of EGF-promoted JB6 Cl41 cell transformation. We reported previously that ERKs are necessary factors in EGF-promoted JB6 Cl41 cell transformation. In the present study, our data show that DN-p38 MAP kinase effectively blocks EGF-promoted JB6 Cl41 cell transformation through inhibition of the phosphorylation of transcription factors, ATF-2 and STAT1, oncogenes, c-Myc, and repression of AP-1 DNA binding. Both p38 kinase and ERKs are involved in the EGF-promoted JB6 Cl41 cell transformation.

 


    FOOTNOTES
 
* This work was supported in part by The Hormel Foundation and National Institutes of Health Grants CA81064, CA88961, and CA77646. The University of Minnesota is an equal opportunity educator and employer. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} To whom correspondence should be addressed: Hormel Institute, University of Minnesota, 801 16th Avenue NE, Austin, MN 55912. Tel.: 507-437-9600; Fax: 507-437-9606; E-mail: zgdong{at}hi.umn.edu.

1 The abbreviations used are: MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; MEK, MAPK/ERK kinase; JNK, c-Jun NH2-terminal kinase; ATF-2, activating transcription factor 2; STAT1, signal transducer and activator of transcription 1; AP-1, activator protein-1; EGF, epidermal growth factor; TPA, 12-O-tetradecanoyl-phorbol-13-acetate; DN-p38, dominant negative mutant p38; MEM, Eagle's minimal essential medium; FBS, fetal bovine serum. Back



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Harper, S. J., and LoGrasso, P. (2001) Cell. Signal. 13, 299–310[CrossRef][Medline] [Order article via Infotrieve]
  2. Ballif, B. A., and Blenis, J. (2001) Cell Growth & Differ. 12, 397–408[Free Full Text]
  3. Papatsoris, A. G., and Papavassiliou, A. G. (2001) Trends Mol. Med. 7, 288–292[CrossRef][Medline] [Order article via Infotrieve]
  4. Herlaar, E., and Brown, Z. (1999) Mol. Med. Today 5, 439–447[CrossRef][Medline] [Order article via Infotrieve]
  5. Tibbles, L. A., and Woodgett, J. R. (1999) Cell. Mol. Life Sci. 55, 1230–1254[CrossRef][Medline] [Order article via Infotrieve]
  6. Whitmarsh, A. J., and Davis, R. J. (1999) Science's STKE http://stke.sciencemag.org/cgi/content/full/sigtrans;1999/1/pe1.
  7. Fan, M., and Chambers, T. C. (2001) Drug Resist. Updat. 4, 253–267[CrossRef][Medline] [Order article via Infotrieve]
  8. Huang, C., Ma, W. Y., Young, M. R., Colburn, N., and Dong, Z. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 156–161[Abstract/Free Full Text]
  9. Qi, X., Pramanik, R., Wang, J., Schultz, R. M., Maitra, R. K., Han, J., DeLuca, H. F., and Chen, G. (2002) J. Biol. Chem. 277, 25884–25892[Abstract/Free Full Text]
  10. Liu, G., Bibus, D. M., Bode, A. M., Ma, W. Y., Holman, R. T., and Dong, Z. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 7510–7515[Abstract/Free Full Text]
  11. Kaminska, B., Pyrzynska, B., Ciechomska, I., and Wisniewska, M. (2000) Acta Neurobiol. Exp. (Warsz.) 60, 395–402[Medline] [Order article via Infotrieve]
  12. Curran, T., and Franza, B. R., Jr. (1988) Cell 55, 395–397[Medline] [Order article via Infotrieve]
  13. Huang, C., Ma, W. Y., Dawson, M. I., Rincon, M., Flavell, R. A., and Dong, Z. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 5826–5830[Abstract/Free Full Text]
  14. Lamb, R. F., Hennigan, R. F., Turnbull, K., Katsanakis, K. D., MacKenzie, E. D., Birnie, G. D., and Ozanne, B. W. (1997) Mol. Cell. Biol. 17, 963–976[Abstract]
  15. Dong, Z., Huang, C., Brown, R. E., and Ma, W. Y. (1997) J. Biol. Chem. 272, 9962–9970[Abstract/Free Full Text]
  16. Greenberg, A. K., Basu, S., Hu, J., Yie, T. A., Tchou-Wong, K. M., Rom, W. N., and Lee, T. C. (2002) Am. J. Respir. Cell Mol. Biol. 26, 558–564[Abstract/Free Full Text]
  17. Nomura, M., Kaji, A., He, Z., Ma, W. Y., Miyamoto, K., Yang, C. S., and Dong, Z. (2001) J. Biol. Chem. 276, 46624–46631[Abstract/Free Full Text]
  18. Ye, J., Zhang, X., and Dong, Z. (1996) Mol. Cell. Biol. 16, 157–167[Abstract]
  19. Colburn, N. H., Wendel, E. J., and Abruzzo, G. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 6912–6916[Abstract]
  20. Eguchi, S., Dempsey, P. J., Frank, G. D., Motley, E. D., and Inagami, T. (2001) J. Biol. Chem. 276, 7957–7962[Abstract/Free Full Text]
  21. Harris, V. K., Coticchia, C. M., Kagan, B. L., Ahmad, S., Wellstein, A., and Riegel, A. T. (2000) J. Biol. Chem. 275, 10802–10811[Abstract/Free Full Text]
  22. Nomura, M., Kaji, A., Ma, W. Y., Zhong, S., Liu, G., Bowden, G. T., Miyamoto, K. I., and Dong, Z. (2001) J. Biol. Chem. 276, 25558–25567[Abstract/Free Full Text]
  23. Zhong, S., Zhang, Y., Jansen, C., Goto, H., Inagaki, M., and Dong, Z. (2001) J. Biol. Chem. 276, 12932–12937[Abstract/Free Full Text]
  24. Zhong, S. P., Ma, W. Y., and Dong, Z. (2000) J. Biol. Chem. 275, 20980–20984[Abstract/Free Full Text]
  25. Liu, G., Zhang, Y., Bode, A. M., Ma, W. Y., and Dong, Z. (2002) J. Biol. Chem. 277, 8810–8816[Abstract/Free Full Text]
  26. Bode, A. M., Ma, W. Y., Surh, Y. J., and Dong, Z. (2001) Cancer Res. 61, 850–853[Abstract/Free Full Text]
  27. Dong, Z., and Cmarik, J. L. (2002) Science's STKE http://stke.sciencemag.org/cgi/content/full/sigtrans;2002/130/pl7.
  28. Battle, T. E., and Frank, D. A. (2002) Curr. Mol. Med. 2, 381–392[Medline] [Order article via Infotrieve]
  29. Mukherjee, B., Morgenbesser, S. D., and DePinho, R. A. (1992) Genes Dev. 6, 1480–1492[Abstract]
  30. al Moustafa, A. E., Quatannens, B., Dieterlen-Lievre, F., and Saule, S. (1992) Oncogene 7, 1667–1670[Medline] [Order article via Infotrieve]
  31. Barrett, J., Birrer, M. J., Kato, G. J., Dosaka-Akita, H., and Dang, C. V. (1992) Mol. Cell. Biol. 12, 3130–3137[Abstract]
  32. Shaulian, E., and Karin, M. (2002) Nat. Cell Biol. 4, E131–E136[CrossRef][Medline] [Order article via Infotrieve]
  33. Eriksson, M., and Leppa, S. (2002) J. Biol. Chem. 277, 15992–16001[Abstract/Free Full Text]
  34. Wisdom, R. (1999) Exp. Cell Res. 253, 180–185[CrossRef][Medline] [Order article via Infotrieve]
  35. New, L., Li, Y., Ge, B., Zhong, H., Mansbridge, J., Liu, K., and Han, J. (2001) J. Cell. Biochem. 83, 585–596[CrossRef][Medline] [Order article via Infotrieve]
  36. Okano, J., and Rustgi, A. K. (2001) J. Biol. Chem. 276, 19555–19564[Abstract/Free Full Text]
  37. Antonyak, M. A., Kenyon, L. C., Godwin, A. K., James, D. C., Emlet, D. R., Okamoto, I., Tnani, M., Holgado-Madruga, M., Moscatello, D. K., and Wong, A. J. (2002) Oncogene 21, 5038–5046[CrossRef][Medline] [Order article via Infotrieve]
  38. She, Q. B., Chen, N., and Dong, Z. (2000) J. Biol. Chem. 275, 20444–20449[Abstract/Free Full Text]
  39. Zoumpourlis, V., Papassava, P., Linardopoulos, S., Gillespie, D., Balmain, A., and Pintzas, A. (2000) Oncogene 19, 4011–4021[CrossRef][Medline] [Order article via Infotrieve]
  40. Ouwens, D. M., de Ruiter, N. D., van der Zon, G. C., Carter, A. P., Schouten, J., van der Burgt, C., Kooistra, K., Bos, J. L., Maassen, J. A., and van Dam, H. (2002) EMBO J. 21, 3782–3793[Abstract/Free Full Text]
  41. Calaf, G., and Hei, T. K. (2001) Int. J. Radiat. Biol. 77, 31–40[CrossRef][Medline] [Order article via Infotrieve]
  42. Ihle, J. N. (2001) Curr. Opin. Cell Biol. 13, 211–217[CrossRef][Medline] [Order article via Infotrieve]
  43. Yu, C. Y., Wang, L., Khaletskiy, A., Farrar, W. L., Larner, A., Colburn, N. H., and Li, J. J. (2002) Oncogene 21, 3949–3960[CrossRef][Medline] [Order article via Infotrieve]
  44. Poselova, T. V., Evdonin, A. L., Medvedeva, N. D., and Pospelov, V. A. (1998) Tsitologiia 40, 1074–1079[Medline] [Order article via Infotrieve]
  45. Caruso, J. A., Reiners, J. J., Jr., Emond, J., Shultz, T., Tainsky, M. A., Alaoui-Jamali, M., and Batist, G. (2001) Mutat. Res. 473, 85–99[Medline] [Order article via Infotrieve]
  46. Yuen, M. F., Wu, P. C., Lai, V. C., Lau, J. Y., and Lai, C. L. (2001) Cancer 91, 106–112[CrossRef][Medline] [Order article via Infotrieve]
  47. Ding, M., Shi, X., Dong, Z., Chen, F., Lu, Y., Castranova, V., and Vallyathan, V. (1999) J. Biol. Chem. 274, 30611–30616[Abstract/Free Full Text]
  48. Sanyal, S., Sandstrom, D. J., Hoeffer, C. A., and Ramaswami, M. (2002) Nature 416, 870–874[CrossRef][Medline] [Order article via Infotrieve]
  49. Dong, Z., Birrer, M. J., Watts, R. G., Matrisian, L. M., and Colburn, N. H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 609–613[Abstract]